Pharmacological Advances in Central Nervous System Stimulants
- 1st Edition, Volume 99 - March 9, 2024
- Imprint: Academic Press
- Editor: Margaret E Gnegy
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 1 9 3 3 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 1 9 3 4 - 4
Pharmacological Advances in Central Nervous System Stimulants, Volume 99 in the Mechanisms, Therapeutic Uses, and Abuse of Stimulants series, showcases recent pharmacologic… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePharmacological Advances in Central Nervous System Stimulants, Volume 99 in the Mechanisms, Therapeutic Uses, and Abuse of Stimulants series, showcases recent pharmacological progress investigating both therapeutic (ADHD, binge-eating and narcolepsy) and abuse aspects of a number of stimulants, some of which are long-standing (amphetamines, cocaine and nicotine) while others are emerging (cathinones). Specific chapters in this new release include Transgenerational Epigenetic Inheritance of Phenotypes Associated with Parental Exposure to Drugs of Abuse, Dysregulation Of Brain Cholesterol Homeostasis by Psychostimulants, Modeling Methamphetamine Use Disorder in Mammals: Sex Differences in Behavioral Consequences and Gene Expression, and much more.
Additional sections focus on Second Generation Stimulants – Pharmacological and Clinical Advances in The Treatment of ADHD And Binge-eating disorder, Pharmacology Of Stimulant – Opioid Co-Use, Role Of Age and Sex in Determining the Risk For Adverse Consequences Following Exposure To Amphetamines, Modafinil, An Atypical CNS Stimulant, Modulators Of Nicotine Reward-Related and Reinforcement-Related Behaviors, Methamphetamine Effects on Peripheral Immune System, Post-Translational Mechanisms in Neurotransmitter Efflux, The Many Enigmas of Nicotine, Genetic Variation in The Neuregulin-Erbb Signaling Pathway And Substance Use Disorders, Pharmacology And Neurotoxicology of Synthetic Cathinones, and more.
Additional sections focus on Second Generation Stimulants – Pharmacological and Clinical Advances in The Treatment of ADHD And Binge-eating disorder, Pharmacology Of Stimulant – Opioid Co-Use, Role Of Age and Sex in Determining the Risk For Adverse Consequences Following Exposure To Amphetamines, Modafinil, An Atypical CNS Stimulant, Modulators Of Nicotine Reward-Related and Reinforcement-Related Behaviors, Methamphetamine Effects on Peripheral Immune System, Post-Translational Mechanisms in Neurotransmitter Efflux, The Many Enigmas of Nicotine, Genetic Variation in The Neuregulin-Erbb Signaling Pathway And Substance Use Disorders, Pharmacology And Neurotoxicology of Synthetic Cathinones, and more.
- Provides a diverse variety of stimulants, having different mechanisms of action and physiological effects
- Includes both therapeutic uses and abuse aspects of stimulants
- Covers both molecular mechanisms and behavioral effects of stimulants
Biomedical scientists and clinicians interested in structural and mechanistic aspects of stimulants from both therapeutic and drug abuse perspectives.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Obituary: S.J. Enna, PhDDecember 19, 1944–June 15, 2023
- Chapter One: Post-translational mechanisms in psychostimulant-induced neurotransmitter efflux
- Abstract
- 1 Introduction
- 2 MAT structure and mechanisms
- 3 Regulation of efflux by transporter phosphorylation
- 4 Regulation of efflux by transporter palmitoylation
- 5 Other efflux mechanisms and relationship to post-translational modifications
- 6 NET and SERT
- 7 Conclusion
- Conflict of interest
- References
- Chapter Two: Cholesterol modulation of interactions between psychostimulants and dopamine transporters
- Abstract
- Abbreviations
- 1 Introduction
- 2 Brain cholesterol and lipid raft microdomains
- 3 Psychostimulants and cholesterol homeostasis
- 4 Membrane cholesterol and the DAT
- 5 Conclusion
- References
- Chapter Three: The pharmacology and neurotoxicology of synthetic cathinones
- Abstract
- Abbreviations
- 1 Introduction
- 2 Synthetic cathinones
- 3 Pharmacology
- 4 Neurotoxicology
- 5 Conclusion
- References
- Chapter Four: Structural and functional perspectives on interactions between synthetic cathinones and monoamine transporters
- Abstract
- Abbreviations
- 1 Introduction
- 2 Monoamine transporters are the main neurobiological targets of cathinones
- 3 In vitro methods to study the pharmacology of monoamine transporters
- 4 Pharmacology of cathinones at monoamine transporters using in vitro assays
- 5 DAT versus SERT in vitro selectivity as a predictor of abuse liability of cathinones in vivo
- 6 Conclusion
- Acknowledgements
- References
- Chapter Five: The role of sex and drug use during adolescence in determining the risk for adverse consequences of amphetamines
- Abstract
- Abbreviations
- 1 Introduction
- 2 Conclusion
- Acknowledgments
- References
- Chapter Six: Modeling methamphetamine use disorder in mammals: Sex differences in behavioral, biochemical, and transcriptional consequences
- Abstract
- Abbreviations
- 1 Introduction
- 2 Effects of sex on the clinical manifestations of METH use disorder
- 3 Sex differences in animal models of METH use disorder
- 4 Conclusion
- References
- Chapter Seven: Epigenetic inheritance of phenotypes associated with parental exposure to cocaine
- Abstract
- Abbreviations
- 1 Introduction
- 2 Epigenetics: the basic molecular framework
- 3 Consequences of parental cocaine exposure on the epigenetic control of gene expression, physiology, and reward-related behavior in subsequent generations
- 4 Conclusion
- Acknowledgments
- References
- Chapter Eight: Immunity on ice: The impact of methamphetamine on peripheral immunity
- Abstract
- Abbreviations
- 1 Introduction
- 2 Methamphetamine regulation of innate immunity
- 3 Impact of methamphetamine on adaptive immune responses
- 4 METH and the dopamine transporter: Implications for peripheral immunity
- 5 Conclusion
- 6 Physiological relevance of experimental models of METH exposure
- Conflict of interest statement
- References
- Chapter Nine: Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
- Abstract
- Abbreviations
- 1 Introduction
- 2 Attention-deficit hyperactivity disorder
- 3 Binge-eating disorder
- 4 Prodrugs
- 5 Pharmacology of drugs to treat ADHD and BED
- 6 Lisdexamfetamine
- 7 Serdexmethylphenidate
- 8 Conclusion
- References
- Chapter Ten: Modafinil, an atypical CNS stimulant
- Abstract
- Abbreviations
- 1 Introduction
- 2 Modafinil pharmacology
- 3 Currently approved, and potential therapeutic uses of modafinil
- 4 Conclusion
- References
- Chapter Eleven: The many enigmas of nicotine
- Abstract
- Abbreviations
- 1 Introduction
- 2 Nicotine enigmas 1, affinity, potency, and diversity of receptors
- 3 Nicotine enigmas 2, varying responses of different nAChR to nicotine
- 4 Nicotine enigmas 3, muscle and ganglionic receptors
- 5 Nicotine enigmas 4, nAChR in brain
- 6 Nicotine enigmas 5, nicotine regulates receptor subunit stoichiometry
- 7 Nicotine enigmas 6, special roles for specific subunits
- 8 Nicotine enigmas 7, the medial habenula
- 9 Nicotine enigmas 8, activation and/or desensitization
- 10 Nicotine enigmas 9, inverted U effects
- 11 Nicotine enigmas 10, nicotine dependence and withdrawal
- 12 Nicotine enigmas 11, not universally addictive
- 13 In conclusion
- Acknowledgments
- References
- Chapter Twelve: Modulators of nicotine reward and reinforcement
- Abstract
- Abbreviations
- 1 Introduction
- 2 Modulators of nicotine
- 3 Conclusion
- References
- Chapter Thirteen: Nicotine use disorder and Neuregulin 3: Opportunities for precision medicine
- Abstract
- Abbreviations
- 1 Introduction
- 2 Neurocircuitry of TUD: Emphasis on reward and affect
- 3 Cellular signaling in TUD
- 4 Mining transcriptional targets for drug development: Neuregulin 3
- 5 Conclusion
- References
- Edition: 1
- Volume: 99
- Published: March 9, 2024
- Imprint: Academic Press
- No. of pages: 312
- Language: English
- Hardback ISBN: 9780443219337
- eBook ISBN: 9780443219344
MG
Margaret E Gnegy
Margaret E. Gnegy is a Professor Emerita (active) in the Department of Pharmacology at The University of Michigan. She received her Ph.D. in Biochemistry in 1975 from West Virginia University. She conducted her post-doctoral studies in the Laboratory of Preclinical Pharmacology at the National Institutes of Mental Health under the tutelage of Dr. Erminio Costa. Her research interests focused on signal transduction mechanisms, particularly protein kinase C, that regulate the action of amphetamine at the dopamine transporter and how they affect reinforcement. In the past few years, her laboratory designed and tested CNS-permeant drugs (PKCβ inhibitors) for inhibition of amphetamine-stimulated dopamine release and amphetamine-stimulated behaviors that assess motivation for drug seeking and taking. For three years Dr. Gnegy served as the Director of the UM Substance Abuse Research Center and for 8 years was the Principle Investigator on the T32 Substance Abuse Interdisciplinary Training Program funded by the National Institutes of Drug Abuse. She also serves as Chair of the Pharmacology Graduate Program for over 20 years. Nineteen pre-doctoral students and 12 post-doctoral fellows have been trained in her laboratory and she has served as mentor to young UM faculty within and outside of the Pharmacology Department. In recognition of her exemplary performance in mentoring and training, the UM conferred upon Dr. Gnegy the Rackham Distinguished Graduate Mentor Award for 2009. She has served as President of both the American Association for Pharmacology and Experimental Therapeutics (ASPET) and the Catecholamine Society. Dr. Gnegy also served as an Associate Editor of the journal Pharmacology & Therapeutics. In 2019 she was named an AAAS Fellow.
Affiliations and expertise
Department of Pharmacology, University of Michigan Medical School, MI, USARead Pharmacological Advances in Central Nervous System Stimulants on ScienceDirect